Your trusted source for investing success

Tag: biomedical

PolarityTE Announces Public Offering of Common Stock

PolarityTE (Nasdaq:COOL), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today announced that it has commenced an underwritten public offering of shares of its

Wave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders

Wave Life Sciences (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics, a biotechnology company that is building a new universe of genetic medicines using its machine learning-driven biomedical platform, today announced the formation of a collaboration to identify novel therapies

Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

Novartis (NYSE:NVS) announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for its portfolio of immuno-oncology therapies.

As quoted in the press release:
“Our collaborators have combined the fields of immuno-oncology and

Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided an update on its development programs.

As quoted in the press release:
“Last week’s release of positive topline data

Clearside Announces Pricing of Public Offering of Common Stock

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of its underwritten public offering of 6,538,462 shares of its common stock at a price to the public of $13.00 per share.

As quoted in the press release:
J.P. Morgan Securities LLC

Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA

Clearside Biomedical (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis.

As quoted in the press release:
Suprachoroidal CLS-TA is Clearside’s proprietary suspension of

Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis

Novartis (VTX: NOVN) has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients. The collaboration brings together Novartis expertise in biomedical research and clinical development with Pear’s leading experience in digital therapeutics design

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Advanced Biomedical Technologies Inc. Announces Chinese CFDA Approval of Polymer Fixation Screws

URL: https://investingnews.com/daily/life-science-investing/medical-device-investing/advanced-biomedical-technologies-inc-announces-chinese-cfda-approval-polymer-fixation-screws/